Compared with single-agent ICB therapy, combination treatment of anti-CTLA4 (ipilimumab) and anti-PDL1 (nivolumab or pembrolizumab) led to better tumor response and patient survival in melanoma, sarcoma, and small cell lung cancer [30–34]. Here, CD274 is linked to sarcoma.